Test Price
130 AED✅ Home Collection Available
Newborn Screening Panel 5 in UAE | 130 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
The Newborn Screening Panel 5 is a preventive metabolic screening assay that detects five critical Inborn Errors of Metabolism from a heel-prick dried blood spot specimen. The test employs quantitative Fluoroimmunoassay (FEIA) methodology with a coefficient of variation below 1.5%, ensuring diagnostic sensitivity exceeding 99.9% under ISO 9001:2015 accredited processing protocols. Results are reported within 24 hours of sample receipt at the laboratory. DNA Labs UAE operates under DHA Facility License 1143 and offers VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection across Dubai and the Northern Emirates. Post-test teleconsultation with a licensed general practitioner is included for clinical result interpretation. Direct billing verification is available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Newborn Screening Panel 5 is a time-sensitive preventive screening test that quantifies specific analyte biomarkers associated with five treatable Inborn Errors of Metabolism. A heel-prick capillary blood sample is applied to a standardized filter paper card, dried under ambient conditions, and subjected to quantitative Fluoroimmunoassay analysis. This method measures antigen-antibody binding via fluorescent signal detection, eliminating the subjective visual interpretation of older colorimetric methods and delivering precise numerical thresholds for pediatric clinical decision-making. The assay is performed under ISO 9001:2015 quality management protocols with stringent internal and external quality control measures.
| Feature | Newborn Screening Panel 5 | Closest Alternative |
|---|---|---|
| Precision | Quantitative FEIA (<1.5% CV) | Semi-Quantitative ELISA |
| Methodology | Fluoroimmunoassay & Specialized Immunoassays | Standard Colorimetric Assay |
| Turnaround Time | Next-Day Reporting | 3-5 Working Days |
Physician Insight & Safety Protocols
"Newborn Screening Panel 5 is a vital public health screening that enables early detection of five treatable metabolic disorders before clinical symptoms emerge. An abnormal screening result is not a diagnosis but a signal requiring urgent confirmatory testing and correlation with the infant's clinical status and feeding history. As a General Practitioner, I emphasize that prematurity, antibiotic exposure, and transfusion history must be meticulously documented on the requisition form to avoid false interpretations. Timely heel-prick collection between 24 and 72 hours of life is critical for test validity."
— Dr. Ajay Singh, General Practitioner (DHA Registration ID: 36234132)
Advisory: Medication Continuation & Clinical Decision-Making
Do not discontinue or alter any prescribed medication for your newborn without explicit consultation with a qualified neonatologist or pediatric specialist. Screening results must always be interpreted within the full clinical context by a licensed medical professional. This panel is a screening tool, not a standalone diagnostic assay. Confirmatory quantitative metabolic testing is mandatory for all abnormal or borderline results before any therapeutic intervention is initiated.
Safety Exclusion Criteria & Emergency Red Flags
- Absolute Exclusion: Neonates who have received a packed red blood cell transfusion within 72 hours prior to sampling. Defer screening until 72 hours post-transfusion.
- Pre-Analytical Rejection Criteria: Insufficient blood volume on filter paper (requires three fully saturated, non-overlapping spots of minimum 8 mm diameter each). Do not layer blood drops.
- Emergency Red Flags: If your newborn exhibits persistent vomiting, profound lethargy, seizures, hypothermia, or poor feeding, proceed immediately to the nearest Emergency Department. Do not wait for screening results before seeking emergency medical attention.
- Specimen Integrity: Keep the dried blood spot card flat and dry at room temperature (18–25°C) in a low-humidity environment. Transport the sample in a sealed, moisture-proof bag with a desiccant pack. Heat exposure above 37°C degrades analyte stability and may invalidate results.
Patient FAQ & Clinical Guidance
1. What is the Newborn Screening Panel 5 and what conditions does it detect?
This panel screens for five treatable Inborn Errors of Metabolism using a dried blood spot specimen collected via heel-prick. The specific analytes measured include biomarkers for phenylketonuria, congenital hypothyroidism, galactosemia, biotinidase deficiency, and glucose-6-phosphate dehydrogenase deficiency. Early detection through this quantitative FEIA-based assay enables prompt dietary or pharmacological intervention before irreversible neurological damage occurs.
2. Why is the quantitative FEIA methodology more accurate than older screening methods?
Quantitative Fluoroimmunoassay directly measures the concentration of each analyte using a fluorescent signal proportional to the target molecule, eliminating the subjective visual grading and high false-positive rates associated with older colorimetric or bacterial inhibition assays. This yields precise numerical thresholds with a coefficient of variation below 1.5 percent, allowing accurate risk stratification and reducing unnecessary repeat testing and parental anxiety.
3. Can I collect the dried blood spot sample at home myself using the provided kit?
Self-collection is not permitted. VIP Mobile Phlebotomy is mandatory to ensure strict adherence to standardized heel-prick depth, proper blood flow, uniform saturation of all three filter paper spots, and immediate initiation of temperature-controlled cold-chain transport. These pre-analytical variables directly impact specimen adequacy and result accuracy. A licensed phlebotomist will visit your residence daily between 8 AM and 11 PM to perform the collection professionally and safely.
4. How is the result reported and what follow-up is provided?
Results are reported within 24 hours of sample receipt at the DNA Labs UAE facility in Dubai Healthcare City. A secure digital report is delivered via email and WhatsApp with a clear interpretive summary. Every result includes a complementary teleconsultation with Dr. Ajay Singh (General Practitioner, DHA Registration ID: 36234132) to explain the clinical implications, recommend confirmatory testing if indicated, and guide next steps in coordination with your pediatrician.
5. Does health insurance cover the cost of the Newborn Screening Panel 5?
Coverage varies by insurance provider and policy. DNA Labs UAE offers direct billing verification through our WhatsApp service at +971 54 548 8731. You can send a photo of your insurance card to our billing team, who will confirm your outpatient laboratory benefits, copayment requirements, and any pre-authorization needs within 30 minutes during business hours. The standard cash price is 130 AED for the complete panel including the post-test teleconsultation.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), governing the lawful collection, processing, storage, and transfer of personal health data. All diagnostic results and patient information are encrypted end-to-end and accessible only to authorized clinical personnel with a legitimate medical need. The laboratory also adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which mandates rigorous cybersecurity standards for electronic health records and telemedicine communications. Clinical safety, specimen collection protocols, and patient consent procedures conform to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that every diagnostic procedure is performed under the direct supervision of a licensed medical practitioner with full informed consent documented before sample collection.
Clinical & Logistical Metadata
| Test Name | Newborn Screening Panel 5 |
| Price (AED) | 130 AED (includes post-test teleconsultation) |
| Turnaround Time | Next-Day Reporting (results delivered within 24 hours of sample receipt) |
| Sample Type / Matrix | Dried Blood Spot (DBS) on standardized filter paper card via heel-prick capillary collection. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Quantitative Fluoroimmunoassay (FEIA) & Specialized Immunoassays, ISO 9001:2015 accredited |
| ICD-10-CM Code | Z13.228 (Encounter for screening for metabolic disorder), Z13.21 (Encounter for screening for inborn errors of metabolism) |
| LOINC Code | 54109-2 (Newborn screening panel - Blood spot) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians